Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc.

ABOS·NASDAQ

$2.37

+2.6%
HealthcareBiotechnology

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

At a Glance

Live Snapshot
Market Cap$143.26M
EPS-2.0000
P/E Ratio-1.18
Earnings Date08/11/2026

abos

Net Cash Provided by Investing Activities

Last Annual Value

133.93M

3-Year CAGR

51%

5-Year CAGR

%

10-Year CAGR

%

Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc. Competitors Analysis of Net Cash Provided by Investing Activities

ABOS · NASDAQ
CompanyNet Cash Provided by Investing Activities
CAGR 3Y
CAGR 5Y
CAGR 10Y
133.93M
N/AN/AN/A 
SEER logo
Seer, Inc.
NASDAQ:SEER
61.55M
17.5%N/AN/A
0.00
N/AN/AN/A
-8.60M
N/AN/AN/A
PEPG logo
PepGen Inc.
NASDAQ:PEPG
-15.23M
N/AN/AN/A
25.48M
-14.8%N/AN/A
0.00
N/AN/AN/A
AGEN logo
Agenus Inc.
NASDAQ:AGEN
27.00K
-80.0%N/A-47.7%
-13.15M
N/AN/AN/A
ALEC logo
Alector, Inc.
NASDAQ:ALEC
196.60M
24.5%N/AN/A
14.04M
-45.6%N/A-1.5%
Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc. Fair Value Envelope

ABOS · NASDAQ

Our analysis suggests that ABOS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.365, this represents a potential HIDDEN relative to our calculated worth for Acumen Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $2.365